ImmunityBio director sells 159,478 shares

ImmunityBio director Christobel Selecky exercised stock options and sold the resulting shares.

Rhea-AI Filing Summary

ImmunityBio director Christobel Selecky exercised stock options and sold the resulting shares. She exercised options covering 124,414 shares at $2.99 per share and 35,064 shares at $2.98 per share, then sold 159,478 shares of Common Stock in open-market transactions at a weighted average price of $9.0236 per share, within a range of $9.00 to $9.07. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. After these transactions, the filing shows she holds no remaining common shares or related options.

Insider Trade Summary 10b5-1

Exercise and Sale: 159,478 shares ($963K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Selecky Christobel

Role Director

Sold 159,478 shs ($1.44M)

Approx. gross sale proceeds $1.44M

Approx. exercise cost $476K

Approx. pre-tax spread $963K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	35,064	$0.00	$0.00
Exercise	Stock Option (right to buy)	124,414	$0.00	$0.00
Exercise	Common Stock	35,064	$2.98	$104K
Exercise	Common Stock	124,414	$2.99	$372K
Sale	Common Stock	159,478	$9.0236	$1.44M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
2. F2. Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 159,478 shares Weighted average sale price: $9.0236 per share Option exercise size 1: 124,414 shares +5 more

8 metrics

Shares sold 159,478 shares Common Stock sold in open-market transactions

Weighted average sale price $9.0236 per share Sales in the $9.00–$9.07 price range

Option exercise size 1 124,414 shares Options exercised at $2.99 per share

Option exercise price 1 $2.99 per share Stock option (right to buy) conversion

Option exercise size 2 35,064 shares Options exercised at $2.98 per share

Option exercise price 2 $2.98 per share Stock option (right to buy) conversion

Net share change -159,478 shares Net-sell direction from transaction summary

Post-transaction holdings 0 shares Total common stock directly owned after transactions

Key Terms

Rule 10b5-1 trading plan, weighted average share price, Stock Option (right to buy, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average share price financial

"Represents the weighted average share price of an aggregate total of 159,478 shares sold"

The weighted average share price is the average price of a stock calculated by giving each recorded trade price a weight proportional to the number of shares traded at that price (or, more generally, by the relevant share quantity for each price). It is computed as the sum of (price × shares) for all transactions divided by the total shares traded, so prices with larger volumes have a bigger effect than low-volume prices; this contrasts with a simple (unweighted) average that treats every price equally.

Stock Option (right to buy financial

"Stock Option (right to buy) ... underlying security title "Common Stock""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmunityBio (IBRX) director Christobel Selecky do in this Form 4?

Director Christobel Selecky exercised stock options and sold the resulting shares. She converted options into 159,478 ImmunityBio common shares, then sold all of them in open-market trades, leaving no common stock holdings reported in this filing.

How many ImmunityBio (IBRX) shares were sold and at what price?

Selecky sold 159,478 ImmunityBio common shares. The weighted average sale price was $9.0236 per share, with individual trades executed in a price range between $9.00 and $9.07, according to the Form 4 footnote disclosure.

What option exercises are reported for ImmunityBio (IBRX) director Selecky?

She exercised options for 124,414 shares at a $2.99 exercise price and 35,064 shares at a $2.98 exercise price. These exercises converted her derivative positions into a total of 159,478 ImmunityBio common shares before the subsequent sales.

Was the ImmunityBio (IBRX) share sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted by Selecky on March 13, 2026. Such plans pre-schedule trades, indicating the timing was set in advance rather than chosen opportunistically.

Does Christobel Selecky still hold ImmunityBio (IBRX) shares after these transactions?

Based on this Form 4, Selecky reports owning zero ImmunityBio common shares directly after the transactions. The derivative entries also show zero remaining option shares, indicating the reported options were fully exercised in connection with these trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 08:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selecky Christobel

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		M		35,064	A	$2.98	35,064	D
Common Stock	07/01/2026		M		124,414	A	$2.99	159,478	D
Common Stock	07/01/2026		S(1)		159,478	D	$9.0236(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.98	07/01/2026		M			35,064	06/12/2023	06/14/2032	Common Stock	35,064	$0	0	D
Stock Option (right to buy)	$2.99	07/01/2026		M			124,414	06/10/2024	06/13/2033	Common Stock	124,414	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.

2. Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)